US2013131122A1PendingUtilityA1
Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions
Est. expiryJul 23, 2023(expired)· nominal 20-yr term from priority
A61P 9/10A61P 9/04A61P 7/06A61P 37/08A61P 7/00A61P 37/06A61P 3/10A61P 43/00A61P 37/02A61P 7/10A61P 5/14A61P 9/00A61P 9/08A61P 35/04A61P 9/12A61P 39/02A61P 9/14A61P 31/06A61P 31/18A61P 25/00A61P 31/10A61P 31/20A61P 35/00A61P 27/06A61P 27/02A61P 35/02A61P 25/02A61P 25/28A61P 33/02A61P 31/16A61P 31/00A61P 33/06A61P 31/04A61P 31/12A61P 29/00A61P 19/02A61P 19/08A61P 11/04A61P 11/16A61P 19/10A61P 1/02A61P 1/00A61P 1/18A61P 17/00A61P 11/06A61P 11/00A61P 17/06A61P 19/00A61P 17/02A61P 13/12A61P 1/04A61P 1/16A61P 15/00C07D 213/62C07D 213/81A61K 31/4412
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound of Formula (I): salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and flt-3.
Claims
exact text as granted — not AI-modified1 - 54 . (canceled)
55 . A compound which is a derivative of a compound of Formula I where the methylamide group is oxidized
56 . A compound claim 2 where the methylamide group is substituted with a hydroxyl group.
57 . A pharmaceutical composition comprising a compound of claim 1 and a physiologically acceptable carrier.
58 . A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of claim 1 and a physiologically acceptable carrier for treating cancer.
59 . A compound which is a derivative of a compound of Formula I where one of the two urea nitrogen atoms is oxidized
60 . A compound claim 5 where either urea nitrogen atom of the compound of formula I is substituted with a hydroxyl group.
61 . A compound which is a derivative of a compound of Formula I where the pyridine nitrogen atom and the methylamide functionality are oxidized
62 . A compound claim 7 where the pyridine nitrogen atom is in the n-oxide form and the methylamide functionality is substituted with a hydroxyl group.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.